Dasatinib and Quercetin (D+Q): The Senolytic Combo Explained
Explore the clinic directoryIn this article
Dasatinib plus quercetin (D+Q) is a two-drug senolytic combination that pairs the prescription leukemia drug dasatinib (Sprycel) with the plant flavonoid quercetin to selectively kill senescent “zombie” cells, first identified by a Mayo Clinic team in 2015 [1]. In old mice it improved physical function and raised post-treatment survival by 36% [2], but human evidence is limited to small pilot trials and one 60-person randomized trial that missed its primary endpoint [6].
D+Q is given in short, intermittent courses rather than daily, and nearly all of the human data come from open-label pilots in people with a specific disease, not from healthy adults trying to slow aging. Dasatinib is a serious prescription drug, so this is not a supplement to self-experiment with casually.
Next step: Use the Directory to find vetted clinics while you research dasatinib and quercetin protocols.
Key Takeaways
- What it is: A two-drug senolytic combo. Dasatinib is an FDA-approved tyrosine kinase inhibitor (brand name Sprycel) used for leukemia. Quercetin is a flavonoid found in onions, apples, and capers and sold as a supplement. Neither is approved by the FDA for aging or senescent-cell clearance.
- How it works: Senescent cells survive by switching on anti-apoptotic defenses. D+Q briefly disables those defenses, tipping the senescent cells into self-destruction. They target different cell types, so the pair covers more ground than either alone, according to Zhu and colleagues at Mayo Clinic (2015) [1].
- What the trials show: Strong mouse data for better physical function and longer lifespan [2]. In humans, small pilots show senescent cells can be cleared [4] and physical function improved in one lung-disease study [3], but no large controlled trial has shown benefit. The first randomized trial, in 60 postmenopausal women, missed its primary bone endpoint, according to Farr et al. (2024) [6].
- Dosing style: Intermittent “hit-and-run” dosing, typically a few consecutive days every few weeks, rather than daily use. The pilots used dasatinib 100 mg with quercetin 1,000 to 1,250 mg per dosing day [3][4].
- Evidence grade: Early. Compelling mechanism and animal data, thin and preliminary human data. Dasatinib carries real prescription-drug risks, including pleural effusion, low blood counts and bleeding.
What are dasatinib and quercetin?
The two halves of D+Q come from very different places. Dasatinib is a tyrosine kinase inhibitor approved by the FDA in 2006, sold as Sprycel, to treat chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia. It is a potent prescription cancer drug, not a supplement. Quercetin is a flavonol found in everyday foods such as onions, apples, berries, and capers, and it is widely available over the counter as a dietary supplement.
On their own, neither was designed to fight aging. They were paired after a deliberate search for compounds that could kill senescent cells, which is how the entire senolytic field began [1].
In research papers the combination appears as D+Q, DQ, or the “senolytic cocktail.” Most of the human work has come from a small network of academic groups: the Kogod Center on Aging at Mayo Clinic, Wake Forest School of Medicine, and UT Health San Antonio. The broader idea of clearing senescent cells is covered in the overview of senolytic drugs, and the main single-compound alternative is in the fisetin explainer.
How does D+Q work in the body?
As cells age or take on damage, some enter a state called senescence. They stop dividing but refuse to die, and they leak a mix of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. These “zombie” cells accumulate with age and are thought to drive chronic inflammation and tissue decline.
Senescent cells survive because they lean heavily on anti-apoptotic defense networks, sometimes called SCAPs (senescent cell anti-apoptotic pathways). In 2015, researchers reasoned that briefly blocking those networks should push senescent cells over the edge into apoptosis, their built-in self-destruct program. Screening identified dasatinib and quercetin as the first drugs that did this [1]. Dasatinib is better at clearing senescent fat-cell progenitors, while quercetin is more effective against senescent endothelial cells, so combining them broadens the range of cell types cleared.
Because senolytics only need to knock out the survival signal long enough to trigger apoptosis, they are given in short, intermittent courses rather than continuously. This “hit-and-run” approach is a defining feature of the class and sets senolytics apart from anti-inflammatory “senomorphic” drugs that must be taken constantly.
Both drugs leave the body quickly. Hickson and colleagues (2019) reported elimination half-lives under 11 hours for dasatinib and quercetin, yet the drop in senescent cells was still measurable 11 days after a three-day course [4]. That gap between short drug exposure and a lasting tissue effect is the core argument for intermittent dosing.
What does the animal evidence show?
The mouse data are the strongest part of the D+Q story. A landmark 2018 study in Nature Medicine showed that senolytics, including D+Q, improved physical function in aged mice and, remarkably, extended their remaining lifespan even when treatment started late in life [2]. Transplanting a small number of senescent cells into young mice was enough to cause physical dysfunction, and clearing those cells with senolytics reversed it. These findings are what pushed D+Q toward human testing.
The size of that effect is specific. Xu and colleagues (2018) reported that intermittent oral D+Q in naturally aged mice increased post-treatment survival by 36% and lowered the mortality hazard to 65% of the untreated rate [2]. The same paper showed that D+Q reduced senescent cells and their inflammatory output in explants of human fat tissue, which linked the mouse work to human biology.
Mouse lifespan results do not translate directly to people. Lab mice live only a few years, are genetically uniform, and are housed in controlled conditions, so a survival gain in mice is a reason to run human trials, not a prediction of what those trials will find.
What do the human trials show?
Human evidence exists, but it is early and should be read with caution. The published trials are small, mostly open-label, and short.
Idiopathic pulmonary fibrosis pilot (2019)
The first-in-human study, published in EBioMedicine in 2019, treated 14 patients with idiopathic pulmonary fibrosis, a serious scarring lung disease linked to cellular senescence. Over three weeks of intermittent D+Q, patients showed improvements in physical-function measures such as walking distance, gait speed, and repeated chair stands. Lung function itself did not change, and there was no placebo group [3].
Justice and colleagues dosed dasatinib 100 mg and quercetin 1,250 mg per day, three days a week for three weeks, and every participant stayed in the study [3]. Pulmonary function, frailty scores, and self-reported health were unchanged, so the signal was limited to physical-performance tests.
Diabetic kidney disease pilot (2019)
A second 2019 EBioMedicine report studied nine people with diabetic kidney disease. After just three days of D+Q, biopsies showed a measurable drop in senescent-cell burden in fat and skin tissue, along with lower levels of several circulating SASP factors. This was the first direct human proof that senolytics actually clear senescent cells in people, rather than only in mice [4].
The participants averaged about 69 years old and took dasatinib 100 mg with quercetin 1,000 mg for three days. Tissue and blood were sampled before treatment and 11 days after it ended, and markers such as p16INK4A, p21CIP1, IL-6, and IL-1α fell over that window [4].
Alzheimer’s disease feasibility trial (2023)
More recently, the SToMP-AD phase 1 feasibility trial, published in Nature Medicine in 2023, gave D+Q to patients with mild Alzheimer’s disease. It was designed to test safety and whether the drugs reach the brain, not to prove benefit. The combo was tolerated and showed evidence of central-nervous-system penetration, setting up larger studies [5].
Gonzales and colleagues enrolled five participants for 12 weeks. Dasatinib was detected in the cerebrospinal fluid of four of them, while quercetin was not detected in cerebrospinal fluid at all, and cognitive and brain-imaging measures did not change from baseline [5].
Bone health in postmenopausal women (2024)
The first randomized controlled trial of D+Q gave a more sobering result. Farr and colleagues (2024) randomized 60 postmenopausal women to intermittent D+Q or control for 20 weeks, and the primary endpoint, a blood marker of bone breakdown called CTx, did not differ between groups [6]. A bone-formation marker rose at 2 and 4 weeks but was back to the control level by 20 weeks, and no serious adverse events were reported.
In exploratory analyses, the women with the highest senescent-cell burden, measured by p16 levels in T cells, responded best, including a gain in wrist bone density [6]. That finding is a hypothesis for future trials, not a result, and it suggests senolytics may only help people who carry a high senescent-cell load.
| Trial (year) | Population | Design | Main finding |
|---|---|---|---|
| Xu et al., Nature Medicine (2018) | Aged mice | Preclinical | Improved physical function and extended remaining lifespan [2] |
| Justice et al., EBioMedicine (2019) | 14 adults with IPF | Open-label pilot | Better walking distance, gait speed, chair stands; no lung-function change [3] |
| Hickson et al., EBioMedicine (2019) | 9 adults with diabetic kidney disease | Open-label pilot | Reduced senescent cells in fat and skin; lower SASP markers [4] |
| Gonzales et al., Nature Medicine (2023) | Adults with mild Alzheimer’s | Phase 1 feasibility | Tolerated; evidence the drugs reached the brain [5] |
| Farr et al., Nature Medicine (2024) | 60 postmenopausal women | Phase 2 randomized controlled trial | No change in the primary bone-resorption marker; exploratory benefit in women with high senescent-cell burden [6] |
What dose was used, and is it safe?
The human pilots used intermittent dosing rather than daily supplements. A representative schedule was dasatinib 100 mg per day plus quercetin 1,000 to 1,250 mg per day for three consecutive days, repeated after a break of days to weeks [3][4]. The logic is that senolytics only need to be present long enough to trigger apoptosis in senescent cells.
| Study | Dasatinib | Quercetin | Schedule |
|---|---|---|---|
| IPF pilot, Justice et al. (2019) | 100 mg per day | 1,250 mg per day | Three days a week for three weeks [3] |
| Diabetic kidney disease pilot, Hickson et al. (2019) | 100 mg per day | 1,000 mg per day | Three consecutive days, once [4] |
| SToMP-AD, Gonzales et al. (2023) | Oral, per trial protocol | Oral, per trial protocol | Two days on, 14 days off, for six cycles over 12 weeks, according to the trial registration (NCT04063124) [5] |
Safety is the part that deserves the most emphasis. Dasatinib is a prescription cancer drug with well-documented risks, including fluid retention and pleural effusion, low blood-cell counts, increased bleeding risk, and heart-rhythm effects. It is not a benign compound. Quercetin is generally well tolerated but can inhibit drug-metabolizing enzymes and interact with medications. The published human trials were short and small, so long-term safety of D+Q as an anti-aging regimen in otherwise healthy people has not been established. Buying dasatinib from gray-market sources to self-dose is genuinely risky and not supported by the evidence.
What are the side effects of dasatinib and quercetin?
The side effects of D+Q come mostly from dasatinib. The drug label and the MedlinePlus dasatinib monograph from the National Library of Medicine list low blood counts, bleeding, fluid buildup around the lungs (pleural effusion), shortness of breath, diarrhea, rash, and heart-rhythm changes among its risks. Those warnings come from people with leukemia taking dasatinib daily, which is far more exposure than a three-day senolytic course.
What side effects did the D+Q trials report?
In the IPF pilot, Justice and colleagues (2019) recorded one serious adverse event across 14 participants, and the most frequent milder events were respiratory symptoms, skin irritation or bruising, and stomach discomfort [3]. The SToMP-AD trial reported no early discontinuations [5], and the 60-woman bone trial reported no serious adverse events [6]. Small trials can miss uncommon harms, so these results describe short-term tolerability, not long-term safety.
Which drug interactions matter?
Dasatinib is broken down mainly by the liver enzyme CYP3A4, so drugs that strongly block or speed up that enzyme change how much dasatinib reaches the blood. Acid-reducing medicines such as antacids and proton pump inhibitors can lower its absorption. Quercetin can also affect drug-metabolizing enzymes, which is why a pharmacist or prescribing physician should review every medication and supplement before any senolytic course.
How does D+Q compare with other senolytics?
D+Q is one of several senolytic approaches, and the alternatives differ in how they are sourced and how much human data exists. Fisetin is a flavonoid sold as a supplement, while navitoclax is an investigational cancer drug that targets the BCL-2 family of survival proteins and is known for lowering platelet counts. Senomorphics such as rapamycin work differently: they quiet the SASP signals of senescent cells instead of killing them, so they are usually taken continuously. The rapamycin and longevity evidence review covers that drug in detail.
| Agent | Type | How it is obtained | Human evidence for aging |
|---|---|---|---|
| Dasatinib plus quercetin (D+Q) | Senolytic combination | Dasatinib by prescription only; quercetin over the counter | Small pilots and one phase 2 randomized trial [3][4][5][6] |
| Fisetin | Senolytic flavonoid | Over-the-counter supplement | Mouse data; human trials still early |
| Navitoclax (ABT-263) | BCL-2 family inhibitor | Investigational cancer drug | No aging trials; low platelets limit use |
| Rapamycin (sirolimus) | Senomorphic, mTOR inhibitor | Prescription only | Early human data; taken continuously or weekly |
Where is D+Q research heading?
The next round of D+Q research is moving from feasibility to controlled trials. The SToMP-AD phase 2 trial (NCT04685590), led by Washington University School of Medicine, is testing the safety and feasibility of senolytic therapy in Alzheimer’s disease and is listed as active but no longer recruiting.
The bone trial changed how researchers think about who should get senolytics. Farr and colleagues (2024) found that the response was concentrated in women with the highest senescent-cell burden [6], and the same team has since characterized T-cell p16 and plasma SASP biomarkers for selecting trial participants. Future D+Q studies are likely to screen for senescent-cell load first, rather than treating everyone of a certain age.
Can you get D+Q from a clinic?
Dasatinib requires a prescription from a licensed clinician, and using it for aging is off-label, cash-pay territory that insurance is unlikely to cover. Hematologist-oncologists prescribe dasatinib for leukemia, while the D+Q research has been led by geriatricians, pulmonologists, nephrologists, and neurologists inside clinical trials. Some longevity and integrative medicine physicians discuss senolytics with patients, and practice varies widely from one clinician to the next.
Regenerated.com has no dedicated senolytic category, so start with longevity-adjacent care. The national directory of NAD+ IV therapy clinics lists practices that work in healthy-aging medicine, and the NAD+ IV therapy treatment guide explains what that service involves and where its evidence stands. A listing tells you a clinic offers a category of care, not that it prescribes D+Q, so ask directly about senolytics, lab monitoring, and how the clinician screens for drug interactions.
Listing order on Regenerated.com is not paid ranking. Featured slots are labeled and capped, Verified means a clinic completed credential checks rather than paid for placement, and the directory is free for patients. Inclusion in the directory is not an endorsement, and the guide to Featured, Verified, and organic listings explains each label.
People researching D+Q are often managing a condition linked to cellular senescence, such as osteoarthritis, where senescent cells accumulate in joint tissue. Senolytics are not an established treatment for any of these conditions, so the condition guides are the better starting point for options that have stronger evidence today.
What has not been shown yet?
The honest summary is that D+Q is a promising idea with real but preliminary human data. What has been shown is that senolytics can reduce senescent-cell burden in humans [4] and that D+Q improved physical function in one small lung-disease study [3]. What has not been shown is that D+Q extends human lifespan, prevents age-related disease, or delivers meaningful anti-aging benefits in healthy adults. Those claims rest on mouse studies and mechanism, not on completed, controlled human trials. Larger randomized trials are underway, and their results will decide whether the mouse promise carries over to people.
The one completed randomized trial points the same way. In 60 postmenopausal women, D+Q did not change the primary marker of bone breakdown at 20 weeks, according to Farr et al. (2024) [6]. No trial has yet tested D+Q against placebo for frailty, disease prevention, or lifespan in healthy older adults.
Frequently asked questions
Is dasatinib available over the counter?
No. Dasatinib is a prescription-only tyrosine kinase inhibitor approved to treat certain leukemias. It is a potent drug with serious potential side effects and is not sold as a supplement. Quercetin, the other half of the combo, is available over the counter, but the dasatinib component requires a prescription and medical supervision.
How is D+Q dosed?
In the human pilot trials, D+Q was given intermittently rather than daily, for example dasatinib 100 mg plus quercetin 1,000 to 1,250 mg for three consecutive days, then a gap of days to weeks before repeating. This “hit-and-run” schedule reflects how senolytics work: they only need to be present briefly to push senescent cells into self-destruction [3][4].
Does D+Q actually clear senescent cells in humans?
Preliminary evidence says yes. In a 2019 pilot in people with diabetic kidney disease, three days of D+Q measurably reduced senescent-cell markers in fat and skin biopsies and lowered several inflammatory SASP factors in the blood. That was the first direct human proof that senolytics clear senescent cells, though it was a small, open-label study [4].
Who should not take D+Q?
D+Q should only be considered under medical supervision, and many people should avoid it entirely. That includes anyone who is pregnant or breastfeeding, people under 18, and anyone on medications that interact with dasatinib or quercetin or that carry bleeding or heart-rhythm risks. Because dasatinib is a serious prescription drug, self-experimentation outside a clinical setting is not advisable [3].
Is D+Q FDA approved for anti-aging?
No. The FDA approved dasatinib, sold as Sprycel, in 2006 for chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia, and it has no approval for aging, frailty, or senescent-cell clearance. Quercetin is sold as a dietary supplement, which the FDA does not review for effectiveness. Any use of D+Q for aging is off-label and is best done inside a registered clinical trial.
Can you take quercetin alone as a senolytic?
Quercetin alone has much weaker senolytic evidence than the combination. In the 2015 Mayo Clinic screening work, quercetin was most active against senescent endothelial cells and dasatinib against senescent fat-cell progenitors, which is why they were paired [1]. In the Alzheimer’s feasibility trial, quercetin was not detected in cerebrospinal fluid [5]. Fisetin, a related flavonoid, is another compound being studied as a stand-alone senolytic.
Bottom Line
Evidence grade: Early. Dasatinib plus quercetin is the founding senolytic combination and has the most complete story in the field: a clear mechanism, strong mouse data showing better function and longer life, and the first human proof that senescent cells can be cleared. But the human trials so far are small, short, and mostly open-label, and no completed controlled study proves anti-aging benefit in healthy people. Just as important, dasatinib is a prescription cancer drug with real risks, which makes casual self-dosing a poor idea. D+Q is one of the most scientifically interesting interventions in longevity research and, at the same time, one to approach with patience and medical oversight rather than enthusiasm alone.
The most useful next step for most readers is a conversation with a clinician who can review medications and labs, or a search for an enrolling senolytic trial on ClinicalTrials.gov. The review of anti-aging supplements and the regenerative medicine for longevity overview put D+Q next to the other options people ask about.
This article is for educational purposes only and is not medical advice. Dasatinib is a prescription drug with serious potential side effects, and both compounds can interact with medications and health conditions. Talk with a qualified healthcare professional before considering dasatinib, quercetin, or any senolytic protocol, especially if you are pregnant, breastfeeding, taking prescription medication, or managing a chronic condition.
Sources
- Zhu Y, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. PMID 25754370 ↩
- Xu M, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID 29988130 ↩
- Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. PMID 30616998 ↩
- Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019. PMID 31542391 ↩
- Gonzales MM, et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nature Medicine. 2023. PMID 37679434 ↩
- Farr JN, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nature Medicine. 2024. PMID 38956196 ↩
